Cargando…

Glycaemic impact of treatment intensification in patients with type 2 diabetes uncontrolled with oral antidiabetes drugs or basal insulin

AIMS: To investigate the impact of treatment intensification (TI) on glycaemic outcomes in patients with type 2 diabetes with glycated haemoglobin A(1c) (A1C) ≥7% after ≥6 months of treatment with 2 oral antidiabetes drugs (OADs) or basal insulin (BI). MATERIALS AND METHODS: Data were extracted from...

Descripción completa

Detalles Bibliográficos
Autores principales:	Buysman, Erin K., Fan, Tao, Blauer‐Peterson, Cori, Miller‐Wilson, Lesley‐Ann
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354816/ https://www.ncbi.nlm.nih.gov/pubmed/30815554 http://dx.doi.org/10.1002/edm2.19

Ejemplares similares

Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents
por: Philis-Tsimikas, A, et al.
Publicado: (2013)

Treatment intensification using long-acting insulin –predictors of future basal insulin supported oral therapy in the DIVE registry
por: Danne, Thomas, et al.
Publicado: (2015)

Efficacy and Safety of IDegLira in Participants with Type 2 Diabetes in India Uncontrolled on Oral Antidiabetic Drugs and Basal Insulin: Data from the DUAL Clinical Trial Program
por: Khunti, Kamlesh, et al.
Publicado: (2017)

Basal Insulin Intensification in Patients with Type 2 Diabetes: A Review
por: Meece, Jerry
Publicado: (2018)

Insulin degludec/liraglutide (IDegLira) maintains glycaemic control and improves clinical outcomes, regardless of pre‐trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulin
por: Meneghini, L., et al.
Publicado: (2019)

Evaluating glycaemic control in patients poorly controlled on oral antidiabetic drugs in real‐world setting: Results from assessing the Appropriate Timing of Type 2 diAbetes INtensification (ATTAIN)
por: Jude, Edward B., et al.
Publicado: (2019)

When glycaemic targets can no longer be achieved with basal insulin in type 2 diabetes, can simple intensification with a modern premixed insulin help? Results from a subanalysis of the PRESENT study
por: Jang, H C, et al.
Publicado: (2008)

Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix® 30) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE™ observational study
por: Gumprecht, J, et al.
Publicado: (2009)

Slow Titration and Delayed Intensification of Basal Insulin Among Patients with Type 2 Diabetes
por: Mocarski, Michelle, et al.
Publicado: (2018)

Multiple uncontrolled conditions and blood pressure medication intensification: an observational study
por: Salanitro, Amanda H, et al.
Publicado: (2010)

Patients with type 2 diabetes inadequately controlled on premixed insulin: effect of initiating insulin glargine plus oral antidiabetic agents on glycaemic control in daily practice*
por: Hammer, H, et al.
Publicado: (2007)

Effectiveness and tolerability of treatment intensification to basal–bolus therapy in patients with type 2 diabetes on previous basal insulin-supported oral therapy with insulin glargine or supplementary insulin therapy with insulin glulisine: the PARTNER observational study
por: Pfohl, Martin, et al.
Publicado: (2015)

Review of basal‐plus insulin regimen options for simpler insulin intensification in people with Type 2 diabetes mellitus
por: Raccah, D., et al.
Publicado: (2017)

Improved Glycaemic Control with Biphasic Insulin Aspart 30 in Type 2 Diabetes Patients Failing Oral Antidiabetic Drugs: PRESENT Study Results
por: Güler, Serdar, et al.
Publicado: (2009)

Intensification of insulin therapy in patients with type 2 diabetes mellitus: An algorithm for basal-bolus therapy
por: Abrahamson, Martin J., et al.
Publicado: (2012)

Delphi-Based Consensus on Treatment Intensification in Type 2 Diabetes Subjects Failing Basal Insulin Supported Oral Treatment: Focus on Basal Insulin + GLP-1 Receptor Agonist Combination Therapies
por: Fadini, Gian Paolo, et al.
Publicado: (2021)

Intensification of Basal Insulin Therapy with Lixisenatide in Patients with Type 2 Diabetes in a Real-World Setting: The BASAL-LIXI Study
por: Bellido, Diego, et al.
Publicado: (2018)

Maintenance of glycaemic control with liraglutide versus oral antidiabetic drugs as add‐on therapies in patients with type 2 diabetes uncontrolled with metformin alone: A randomized clinical trial in primary care (LIRA‐PRIME)
por: Unger, Jeff, et al.
Publicado: (2021)

Basal insulin intensification with GLP-1RA and dual GIP and GLP-1RA in patients with uncontrolled type 2 diabetes mellitus: A rapid review of randomized controlled trials and meta-analysis
por: Lisco, Giuseppe, et al.
Publicado: (2022)

Burden of illness and costs associated with eosinophilic granulomatosis with polyangiitis: evidence from a managed care database in the United States
por: Bell, Christopher F, et al.
Publicado: (2021)

Clinical outcomes of basal insulin and oral antidiabetic agents as an add-on to dual therapy in patients with type 2 diabetes mellitus
por: Cheng, Chih-Ning, et al.
Publicado: (2020)

LBSUN319 Characteristics And Treatment Patterns Of Hispanic/latino Patients Initiating First Injectable Glp-1ra Or Basal Insulin
por: Hoog, Meredith, et al.
Publicado: (2022)

Impact of delaying treatment intensification with a glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes uncontrolled on basal insulin: A longitudinal study of a US administrative claims database
por: Tong, Liyue, et al.
Publicado: (2017)

Budget Impact of Oral Semaglutide Intensification versus Sitagliptin among US Patients with Type 2 Diabetes Mellitus Uncontrolled with Metformin
por: Wehler, Elizabeth, et al.
Publicado: (2020)

FRI638 Glycemic And Cost Outcomes In Hispanic/Latino People With Type 2 Diabetes Initiating Dulaglutide Or Basal Insulin In The US
por: Hoog, Meredith, et al.
Publicado: (2023)

Use of glucagon‐like peptide‐1 receptor agonists among individuals on basal insulin requiring treatment intensification
por: Trautmann, M. E., et al.
Publicado: (2018)

A Relative Cost of Control Analysis of IDegLira versus Other Forms of Basal Insulin Intensification in Mexico
por: Garnica-Cuellar, Juan Carlos, et al.
Publicado: (2023)

How many oral antidiabetic drugs before insulin?
por: Kelwade, Jayant, et al.
Publicado: (2017)

Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA
por: Mauricio, Dídac, et al.
Publicado: (2017)

Glycaemic control efficacy of oral antidiabetic drugs in treating type 2 diabetes: a protocol for network meta-analysis
por: Jia, Yongliang, et al.
Publicado: (2015)

Stepwise intensification of insulin therapy in Type 2 diabetes management—exploring the concept of the basal-plus approach in clinical practice
por: Owens, D R
Publicado: (2013)

IDegLira Versus Alternative Intensification Strategies in Patients with Type 2 Diabetes Inadequately Controlled on Basal Insulin Therapy
por: Freemantle, Nick, et al.
Publicado: (2015)

Intensification of Insulin Therapy for Type 2 Diabetic Patients in Primary Care: Basal-Bolus Regimen Versus Premix Insulin Analogs: When and for whom?
por: Mosenzon, Ofri, et al.
Publicado: (2013)

The Postprandial-to-Fasting Serum C-Peptide Ratio is a Predictor of Response to Basal Insulin-Supported Oral Antidiabetic Drug(s) Therapy: A Retrospective Analysis
por: Mu, Pan-wei, et al.
Publicado: (2018)

Basal insulin initiation in primary vs. specialist care: similar glycaemic control in two different patient populations
por: Orozco‐Beltran, D., et al.
Publicado: (2016)

Glycaemic profiles of diverse patients with type 2 diabetes using basal insulin: MOBILE study baseline data
por: Peters, Anne, et al.
Publicado: (2020)

Patient‐led rapid titration of basal insulin in gestational diabetes is associated with improved glycaemic control and lower birthweight
por: McGovern, Andrew P., et al.
Publicado: (2022)

When basal insulin is not enough: A dose–response relationship between insulin glargine 100 units/mL and glycaemic control
por: Umpierrez, Guillermo E., et al.
Publicado: (2019)

588. Retrospective Analysis of Clinical Characteristics and Treatment Patterns Among HIV Patients with Commercial and Medicare Advantage Health Insurance in the United States
por: Priest, Julie, et al.
Publicado: (2018)

Differential Treatment Response to Insulin Intensification Therapy: A Post Hoc Analysis of a Randomized Trial Comparing Premixed and Basal-Bolus Insulin Regimens
por: Shi, Li Xin, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_pm85tmpn5agrkl91nde65daddk